The FDA appointed permanent leaders for drugs, vaccines and biologics, and tobacco, naming Dr Michael Davis to oversee drug reviews including upcoming psychedelic therapies.

The Trump administration filled four senior FDA roles after months of turnover. Dr Michael Davis will lead the Center for Drug Evaluation and Research and oversee reviews of psychedelic drugs being studied for psychiatric conditions, including psilocybin, MDMA and LSD, as officials push to accelerate reviews.